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Catalunya, C/ Eduard Maristany, 10-14, Ed. I2, 08019, Barcelona, Spain. 
Correspondence to: luis.javier.del.valle@upc.edu and carlos.aleman@upc.edu 
  
2 
 
ABSTRACT 
Poly(3,4-ethylenedioxythiophene) (PEDOT) nanoparticles have been loaded with 
curcumin and piperine by in situ emulsion polymerization using dodecyl benzene 
sulfonic acid (DBSA) as both stabilizer and doping agent. The loaded drugs affect the 
morphology, size and colloidal stability of the nanoparticles. Furthermore, kinetics 
studies of non-stimulated drug release have evidenced that polymer···drug interactions 
are stronger for curcumin than for piperine. This observation suggests that drug delivery 
systems based on combination of the former drug with PEDOT are very appropriated to 
show an externally tailored release profile. This has been demonstrated by comparing 
the release profiles obtained in presence and absence of electrical stimulus. Results 
indicate that controlled and time-programmed release of curcumin is achieved in a 
physiological medium by applying a negative voltage of –1.25 V to loaded PEDOT 
nanoparticles. 
 
Keywords: Anticancer Agent; Conducting polymer; Curcumine; Controlled release; 
Piperine  
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1. Introduction 
Electroactive conducting polymers (ECPs) allow excellent control of the electrical 
stimulus, possess very good electrical and optical properties, have a high 
conductivity/weight ratio and can be biocompatible, biodegradable and porous.
[1]
 
Furthermore, a great advantage of ECPs is that their properties can be tailored to the 
specific needs of their applications by incorporation of biopolymers, peptides, or other 
bio-related moieties.
[2]
  
On the other hand, on-demand release of drug molecules from biomedical devices 
enables precise targeted dosing that can be temporally tuned to meet requirements for a 
variety of biomedical applications.
[3,4]
 Recent advances have facilitated the use of 
different stimuli, such as light, magnetic and electric fields, ultrasounds and 
electrochemical signals, to trigger drug release from smart material formulations (e.g. 
films, micro- and nanoparticles, and implant devices).
[4,5]
 These technologies enable 
greater control over drug delivery compared to traditional systems that cannot be 
modified in response to changing therapeutic needs (e.g. systems based on 
biodegradability of polymers).  
Electro-responsive drug-delivery systems are particularly attractive in this regard 
because electrical signals can be generated relatively easily, be accurately controlled 
and be remotely applied without using large, specialized and complex equipment. 
Moreover, it is possible to develop drug-delivery systems that allow repetitive dosing. 
In particular, recent in vivo assays have proved that ECPs nanoparticles (NPs) are 
successful electro-responsive drug delivery systems.
[6,7]
 Thus, the application of a small 
external electric field to these systems, which were subcutaneously localized by syringe 
injection at the place of interest, released the drug from the NPs, allowing its diffusion 
to the surroundings. 
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At present time, the existence of multiple methods to incorporate drugs into ECP 
matrices for their subsequent release indicates that these organic materials are potential 
platforms for controlled drug delivery.
[8]
 For example, molecules bound in ECPs films
[9]
 
through doping can be controllably expelled by applying a reducing electrical potential. 
Thus, the fact that they can be made porous and have delocalized charge carriers aids in 
the diffusion of the bound molecules, adding a further reason why ECPs are very 
suitable for drug release applications.
[10]
 Nevertheless, formulations based on ECPs thin 
films, which are the most frequent ones, present low drug loading as a major 
disadvantage.
[11]
 Although more drug can be incorporated by increasing the thickness of 
the films, the majority of the release takes place at the surface while drug molecules at 
the bulk remain. Compared to films, ECP NPs have increased surface-to-volume 
ratio,
[12]
 allowing higher drug loading. In spite of their small size, ECP NPs are 
electrically and electrochemically responsive, which is expected to be very 
advantageous for the design of controllable and programmable drug delivery systems. 
Considering the vast amount of possibilities, ECP NPs will undoubtedly play a decisive 
role in all disciplines of sciences that require programmed delivery of chemical 
compounds, including the biomedical field.  
In some recent but still scarce studies, NPs of polypyrrole (PPy), which is probably 
the most studied non-toxic ECP,
[13]
 has been used to trigger sensitive dosage-controlled 
release of drugs.
[6,14,15]
 More specifically, the response of PPy NPs embedded in a 
hydrogel against a dual stimulus (temperature and electric field) was demonstrated 
through in vivo experiments.
[6]
 Additionally, the on demand release of drugs with 
different polarities and molecular weights from electroresponsive PPy NPs has been 
evaluated.
[14]
 The biocompatibility and linear response achieved with a repetitive and 
pulsed release evidenced that such approaches are facile and minimally invasive for 
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potential medical applications.
[6,14]
 Besides, the pH-sensitive behavior of drug loaded 
PPy NPs has been also reported,
[15]
 reflecting that the release can be controlled through 
the pH, the charge of the drug and/or the addition of charged amphiphiles. 
Among ECPs, poly(3,4-ethylenedioxythiophene) is probably the most employed for 
the fabrication of biomedical devices because of its outstanding capacitive performance, 
fast doping-undoping process, stable charge-discharge response, and high conductivity, 
biocompatibility and stability in continuous operation.
[16-18]
 The structure, surface 
morphology and porosity of PEDOT and the above discussed PPy are completely 
different
[17,19]
 since the former is exclusively formed by ,-linkages while the latter is 
highly crosslinked. Consequently, both the electrochemical and electrical responses of 
PEDOT are greatly superior to those of PPy. In spite of these advantages, the loading of 
drugs into PEDOT NPs for release on demand remains practically unstudied. Paradee 
and Sirivat
[20]
 examined the electrically-controlled release of benzoic acid loaded on 
PEDOT NPs blended with alginate hydrogels. More recently, Liu et al.
[21]
 loaded 2-
phenylethynesulfonamide, which is a heat shock protein 70 (HSP70) inhibitor, into 
thermo-responsive poly(N-isopropylacrylamide) shells, incorporating PEDOT NPs as 
photothermal coupling agent.  
In this work two neutral and hydrophobic drugs have been loaded into PEDOT NPs 
(drug/PEDOT NPs) during their synthesis by emulsion polymerization in water. These 
drugs are curcumin (CUR), which displays a wide spectrum of medical properties 
ranging from anti-bacterial, anti-viral, anti-protozoal, anti-fungal, and anti-inflammatory 
to anti-cancer activity,
[22]
 and piperine (PIP), a piperidine alkaloid with pharmacological 
properties as anti-inflammatory, antifertility and stimulator of serotonin synthesis in the 
central nervous system, among others.
[23]
 The release of the drugs from the ECP NPs 
has been investigated without and with electrostimulation. Results have demonstrated 
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that PEDOT NPs loaded with CUR serve as a drug reservoir for electric-field triggered 
release. 
 
2. Results and discussion 
Although different approaches have been proposed to synthesize ECP NPs from their 
corresponding monomers combined with soft-templates,
[24]
 they have been criticized 
because of the poor control on both size and colloidal stability. Moreover, the difficulty 
of getting rid of the surfactant is added.
[25]
 In a recent study, Zhou and coworkers 
prepared PEDOT NPs with a particle size distribution of 17.2±1.6 nm applying a 
hydrothermal approach and using FeCl3·6H2O as oxidant and sodium dodecyl benzene 
sulfonate as stabilizer.
[26] 
In the present study, PEDOT NPs have been obtained in water 
at 40 ºC using dodecyl benzene sulfonic acid (DBSA) as stabilizer and doping agent 
simultaneously, and ammonium persulfate (APS) as oxidizing agent (Figure 1b). It is 
worth noting that the stabilizer is required to avoid the yielding of the ECP as an 
insoluble bulk powder with very limited processability.
[27]
 The effective diameter (Deff) 
of the resulting PEDOT NPs, which are displayed in Figure S1, was 356 and 842 nm, 
as determined by scanning electron microscopy (SEM) and dynamic light scattering 
(DLS), respectively.  
The two drugs, CUR and PIP (Figure 1c), considered in this work were loaded in situ 
during the emulsion polymerization. Due to their hydrophobicity, the drugs remained 
into the cores of the surfactant micelles rather than interacting with the medium. After 
polymerization, PEDOT NPs were formed and drugs were successfully loaded. The 
drug loading ratio (DLR), which was expressed as mass of encapsulated drug with 
respect to the total mass, was 5.91.6% and 8.00.4% for CUR and PIP, respectively, 
these values being similar to those achieved using other polymeric vesicles.
[28]
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Moreover, the successful loading of the drugs within the PEDOT NPs was further 
confirmed by FTIR spectroscopy, discussed afterwards.  
CUR- and PIP-loaded PEDOT NPs, hereafter denoted as CUR/PEDOT and 
PIP/PEDOT NPs, respectively, are spherical and stable in solution (Figure 2). Despite 
the CUR and PIP are neutral, hydrophobic and of similar size (i.e. 368.4 g/mol and 
285.3 g/mol, respectively), the average effective diameter (Deff) of loaded NPs was 
found to be considerably affected by the drug, as observed by DLS measurements and 
SEM measurements. Table 1 reflects that the CUR/PEDOT NPs are small and 
monodisperse (i.e. Deff with low standard deviation), whereas PIP/PEDOT NPs are 
relatively large and polydisperse (i.e. Deff  with high standard deviations). The yielded 
NPs and their corresponding aggregates successfully remained below 4 µm, which is the 
smallest diameter of human blood capillaries,
[29]
 and thus avoiding the blockage of 
blood vessels or the possibility of being eliminated by the body reticuloendothelial 
system. 
SEM and DLS observations are corroborated by the atomic force microscopy (AFM) 
images displayed in Figure 3, which reflect remarkable differences among PEDOT, 
CUR/PEDOT and PIP/PEDOT NPs. Thus, PEDOT NPs remained stable and very small 
while CUR/PEDOT and, especially, PIP/PEDOT exhibited higher size and tendency to 
aggregate. The size increment is probably due to the extremely low aqueous solubility 
of the two drugs, which promotes the formation of relatively large molecular cores 
inside PEDOT NPs. The tendency to aggregate is corroborated by the zeta- (-) 
potential, which varies as follows: PEDOT < CUR/PEDOT < PIP/PEDOT (Table 1). 
The physical stability of an aqueous dispersion is considered to be good when the 
absolute value of the -potential is around 30.[30] Therefore, the colloidal stability of 
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CUR/PEDOT and PIP/PEDOT NPs (-potential of -26.5±5.1 and -18.7±3.0 mV, 
respectively) is lower than that of PEDOT NPs (-29.4±3.6 mV). 
FTIR spectroscopy has been used to determine the chemical structure of the 
functional groups on the surface of PEDOT NPs. Figure 4 displays the FTIR spectra 
recorded for drugs, PEDOT NPs and drug/PEDOT NPs. PEDOT NPs doped with 
DBSA exhibit the main absorption peaks from the thiophene, ether and sulfonate 
groups: stretching modes of C=C in the thiophene ring at 1647 and 1557 cm
-1
, CH2 
stretching modes at 1478, 1396 and 750 cm
-1
, C–O–C vibrations at 1206 and 1057 cm-1, 
and the S–O stretch at 667 cm-1.  
The addition of drugs during the polymerization process did not affect the 
localization of PEDOT bands; instead, the bands associated to the individual drugs were 
appreciated proving their incorporation. The two main characteristic C=O stretching 
bands at 1626 and 1535 cm
-1
 and the enol C–O peak at 1267 cm-1 observed for CUR 
alone are also detected in CUR/PEDOT NPs (Figure 4a). Similarly, the very broad band 
at 3293 cm
-1
 and the sharp peak at 3508 cm
-1
 indicate the presence of OH, whereas the 
peaks at 959 and 713 cm
-1
 have been attributed to the benzoate trans- and cis-CH 
vibrations, respectively. Finally, the FTIR spectrum of free PIP (Figure 4b) clearly 
shows the characteristic C=O stretching peaks at 1628 and 1545 cm
-1
, which are 
preserved in PIP/PEDOT NPs.  
Dialysis bags with a molecular weight cut-off of 3500 KDa were used to understand 
the kinetics of the non-stimulated drug release in different media (Figure 5). In order to 
achieve a complete CUR and PIP release, three different environments with increasing 
affinity for the drug were examined: PBS with 0.5% Tween 20 (which is a surfactant 
that helps the dissolution of the drug), and the same solution mixed with 10% ethanol 
(EtOH) and with 70% EtOH. Comparison of the released amount of drug from 
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drug/PEDOT NPs with their respective controls (i.e. drugs alone) allows to visualize a 
different behaviour for CUR and PIP when interact with PEDOT. More specifically, the 
release of CUR from CUR/PEDOT NPs was much slower than that of PIP from 
PIP/PEDOT NPs with respect to their corresponding controls. These results reflect a 
relatively strong interaction between CUR and PEDOT, making difficult the release of 
the drug from the NPs until an environment with a high alcoholic content is used 
(Figure 5a). Instead, the release of PIP from the NPs was very similar to that of the 
control, indicating a simple diffusion phenomenon motivated by the poor affinity 
between the drug and the ECP. This feature is confirmed by the almost imperceptible 
effect of the increment of EtOH in the release medium (Figure 5b). The divergent 
behaviour of CUR/PEDOT and PIP/PEDOT should be attributed to the different 
hydrogen bonding abilities of the two drugs. Thus, CUR···PEDOT hydrogen bonds are 
expected to be formed between the hydroxyl groups of CUR (Figure 1c) and the 
dioxane rings of PEDOT. It should be noted that this kind of specific interactions were 
found to play a crucial role in DNA···PEDOT interactions,
[31]
 which are highly 
dependent on the DNA sequence. In contrast, the absence of groups able to act as 
hydrogen bonding donors in PIP precludes the formation of PIP···PEDOT hydrogen 
bonding interactions. Overall, these results suggest that CUR/PEDOT NPs are 
promising candidates to behave as electrically responsive drug delivery systems.  
Before of the electrostimulation studies, the electrochemical response of CUR, PIP, 
and both PEDOT and drug/PEDOT NPs was examined by cyclic voltammetry (CV), 
registering oxidation–reduction cycles within the potential range of -1.5 to + 1 V at 
different scan rates. Figure 6a (left) displays a photograph of the three electrode 
configuration when cyclic voltammetry was recorded from CUR/PEDOT NPs deposited 
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on GCE. Interestingly, it was possible to visualize the release of CUR from the NPs 
when low scan rates were employed.  
Cyclic voltammograms recorded for CUR and PIP are displayed in Figures S3a and 
S3b, respectively. Since CUR molecule contains two hydroxyl groups a conjugation 
effect can occur from the electron cloud deviation. As can be it seen CUR exhibits one 
well defined anodic peak at a potential of  +0. 4 V and a less defined cathodic peak at 
 -0.10 V (Figure S3a), which are similar to that previously observed elsewhere.[32]. 
These quasi-reversible peaks have been attributed to the product of the irreversible 
oxidation reaction, which can be adsorbed onto the electrode surface. The intensity of 
the peaks increases in absolute value with the scan rate and, in addition, the peaks 
potential shift slightly indicating that they correspond to a quasi-reversible redox 
process.
[33]
 Instead, the voltammograms recorded for PIP exhibit two irreversible anodic 
peaks at 0.12 V and 0.92 V.  
Cyclic voltammograms of PEDOT, CUR/PEDOT and PIP/PEDOT NPs adsorbed 
onto glassy carbon electrodes are compared in Figures 6b-d. The current density 
increases proportionally with the scan rate suggesting that the electrochemical process 
depends on the difussion.
[34]
 Moreover, detailed inspection of the voltammograms 
recorded for CUR/PEDOT NPs allows identification of the CUR anodic peak at a 
potential between 0.4 and 0.5 V, depending on the scan rate. Figure 6e plots the current 
density at the anodic and cathodic peaks (jp) of CUR against the square root of the scan 
rate, while Figure 6f represents the same graphic for the irreversible anodic process of 
PIP at 0.92 V. A linear behavior is observed in all cases. Moreover, in the case of CUR 
the slope was slightly higher for the anodic process than for the cathodic one. These 
results confirm the dependence of electrode reaction on the diffusion, which is the mass 
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transport rate of the electroactive species to the surface of the electrode across a 
concentration gradient.  
Experiments with electrostimulation were performed using a conventional three-
electrode setup, similar to that displayed in Figure 6a, with glassy carbon coated with 
drug/PEDOT NPs as working electrode (WE), bare glassy carbon as counter electrode 
(CE), and AgAgCl as reference electrode (RE). To investigate the effect of the voltage 
on the release of CUR and PIP from drug/PEDOT NPs, different voltages (i.e. 0.50 V, 
−0.50 V, −1.00 V and −1.25 V) were applied during 3 min. Results have been compared 
with control experiments, which were performed in absence of electric voltage 
(hereafter denoted 0.00 V). In order to mimic a physiological medium, electrically 
stimulated drug release experiments were performed using PBS 1 with 0.5 % (v/v) 
Tween 20 at pH 7.4 as electrolyte medium.  
Results found for CUR and PIP, which are displayed in Figures 7a and 7b, 
respectively, demonstrate completely different behaviours. The percentage of released 
CUR with respect to the amount of encapsulated CUR was lower than 5% when the 
applied voltage was 0.50 V or in absence of stimulus, while increased progressively and 
linearly with the more negative voltage. Thus, the stimulation with −1.25 V for 3 min 
resulted in a CUR delivery of 38%. In the case of PIP/PEDOT NPs, the amount of 
released drug in absence of stimulus is 10%, increasing to 18% and 23% when the 
applied voltage is −0.50 and 0.50 V, respectively. No systematic behaviour was 
identified in the case of PIP (Figure 7b), indicating that the release of this drug cannot 
be controlled and programmed through electrostimulation. 
Figures 7c and 7d display the release of CUR and PIP, respectively, from 
drug/PEDOT NPs with time. Results from these experiments, which were performed 
using a fixed voltage of −1.25 V, are consistent with those reported in Figures 7a and 
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7b, indicating that controlled release by electrical stimulation can be efficiently 
achieved only for CUR. Thus, although 7% of CUR is released after 30 s only, the 
amount of released drug increases logarithmically with time. In the time interval 
compressed between 3 and 9 min, the release grows from 38% to 60%. Also, 
complementary assays showed that the CUR release stops when the voltage is tuned off, 
proving that this is a regulated process. These results reflect that the controlled CUR 
release can be achieved with both time and applied potential (Figures 7a and 7c, 
respectively). Release profiles were reproducible not only with as fresh samples but also 
with suspensions that were stored for even one month before the release assays. The 
variation of PIP release with time is practically null (i.e. 20% after both 3 and 9 min), 
corroborating that the poor interactions between such drug and the ECP preclude the 
applicability of PIP/PEDOT NPs as dosage-controlled drug delivery vehicles.  
Previous studies suggested that the take-up and rate delivery of drugs may depend on 
the structure, composition and oxidation state of the ECP.
[11]
 In the particular case of the 
release of charged drugs by electrical stimulation, the main factor is the oxidation state 
since the driving force of this process is the apparition of repulsive drug···ECP 
electrostatic interactions. Thus, the oxidation and reduction of the ECP cause the release 
of cationic and anionic drugs, respectively.
[11]
 However, CUR and PIP are neutral drugs 
at pH= 7 and, therefore, their electrically stimulated release is expected to be controlled 
by a more complex mechanism. Unfortunately, designs allowing for the controlled 
release of neutral drugs are very scarce. Langer and co-workers
[35]
 used biotin-doped 
PPy to load biotinylated nerve growth factor (NGF) at the biotin binding sites found at 
the polymer surface. Reduction of the PPy film resulted in an electrically triggered NGF 
release, which remained biologically active. On the other hand, N-methylphenpthiazine 
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(NMP) loaded into PPy doped with anionic β-cyclodextrins was released when 
oxidized, which caused the formation of positive charges on both the ECP and NMP.
[36]
  
The mechanism proposed in this work for the electrically stimulated release of CUR 
is based on the effect of the voltage on the oxidation state of the ECP and, therefore, on 
PEDOT···CUR interactions. The release of CUR is not stimulated by the application of 
the positive voltage (+0.50 V), which enhances the positive oxidation state of the 
polymer (Figure S3) while the oxidation of the drug starts at around such potential 
(Figure S3). In contrast, the CUR release becomes electrostimulated upon the 
application of negative voltages, which induce the electrochemical de-doping 
(reduction) of PEDOT NPs. Thus, the fraction of reduced PEDOT sites over the number 
of total active sites (i.e. where electrons are exchanged) increases with the negative 
voltage, polymer chains being expected to be completely, or almost completely, reduced 
(i.e. de-doped – with neutral charge) at the voltage of –1.25 V.[34] It was observed that 
lower voltages caused mechanical and electrochemical degradation of the ECP NPs. 
The de-doping of the ECP affects the intermolecular interactions with the drug, 
hydrogen bonds being significantly weaker when PEDOT chains are in the neutral state 
than in the oxidized state.
[37]
 Accordingly, the mechanism for the electrostimulated 
CUR release from CUR/PEDOT NPs can be summarized by the following Eqn: 
(PEDOT
+
·DBSA–)···nCUR + e–   
(PEDOT
(-)+
·(-)DBSA–)···mCUR + DBSA– + (n-m)CUR 
where nCUR refers to the drug molecules hydrogen bonded to the oxidized 
polymeric NPs, mCUR corresponds to the drug molecules that remain hydrogen bonded 
to the polymeric NPs after pump  electrons into the system by electrical stimulation, 
and + and (-)+ are the oxidation states of oxidized and reduced PEDOT, 
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respectively (i.e. when PEDOT is completely reduced, =, the charge of the ECP is 
zero.  
The release mechanism proposed in this work for neutral drugs able to form specific 
interactions with the ECP matrix resembles that typically reported when negatively 
charged drugs act as dopant ions.
[8]
 Unfortunately, this mechanism does not apply to 
PIP/PEDOT NPs because of the lack of hydrogen bonding donors in the drug. 
Accordingly, PIP molecules are rapidly released by through the walls of the polymeric 
NPs, such diffusion process being independent of the presence or not of external 
stimuli. Thus, although the application of an electric voltage affects the oxidation state 
of PEDOT chains, it does not improve the control in the release that is determined by 
the intrinsically weak dispersion interactions between PIP molecules and the aromatic 
rings of the ECP.  
In order to overcome the limitations associated to the instability in the light, poor oral 
bio-availability in vivo and lack of solubility in aqueous solvents of CUR, the use of 
micro- and nanoparticles made of polymer materials, as for example poly(lactic-co-
glycolic acid), as carriers has been extensively explored.
[38]
 Although polymeric micro- 
and nanoparticles provided biocompatibility, in some cases also biodegradable, 
platforms for sustained release of CUR with improved bio-availability, several 
disadvantages were detected. The most important one, which is the effective control 
during the release, has been overcome in this work applying a controlled voltage to 
electrodes coated with CUR/PEDOT NPs, achieving a programmed CUR release.  
The biocompatibility and cytotoxicity of such system is an important characteristic to 
be analyzed for further biological applications. PEDOT NPs and the surfactant (DBSA) 
alone were tested in epithelial-like prostate and breast adenocarcinoma cells lines from 
human (PC3 and MCF-7, respectively) using the MTT assay measured after 24 h post-
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treatment (Figure 8a). PEDOT NPs do not exhibit any toxic effect until they are used at 
high concentration. Moreover, it is clearly demonstrated that, after the 3 washing steps, 
the quantity of dopant is lower than 6 µg/mL, when DBSA starts to be toxic. The 
cytotoxicity of free CUR and CUR/PEDOT NPs, which was evaluated at 24 h post-
treatment using the same cell lines, reflects significant concentration dependence 
(Figure 8b). Significant differences are observed in the behaviour of the two systems, 
free CUR being considerably more toxic than CUR/PEDOT NPs. More specifically, for 
PC3 the half-maximal inhibitory concentration (IC50) of the former and the latter is 
around 20 and 100 µg/mL, respectively, while for MCF-7 both are around 10 µg/mL. 
These results, combined with the fact that the drug loaded inside the NPs is only 
partially released in absence of external stimuli, corroborate that PEDOT nanostructures 
formed by emulsion polymerization is a very interesting electroactive vehicle for the 
controlled delivery of neutral drugs having groups able to interact with hydrogen bonds. 
In order to explore the mechanisms of cytotoxicity, the cellular uptake of free CUR 
and CUR/PEDOT NPs on PC3 and MCF-7 cells was observed by fluorescence 
microscopy. Figure 9 shows the images of non-treated cells, PEDOT NPs treated, free 
CUR treated and CUR/PEDOT treated for 24 h. Medium without treatment drug was 
regarded as control, as well as, the PEDOT NPs treated group. Both groups did not 
present any fluorescence at any point and there was not any diminish in cell nucleus 
number. In contrast, an intense fluorescence was observed at the cell cytosol after 24 h 
for free CUR and CUR/PEDOT NPs. In addition, the two groups exhibited lower 
number of cell nuclei than before the treatment had been executed. Besides, different 
cellular morphologies were observed: cells treated with free CUR presented more 
rounded bodies, denoted by high circularity (Figure 9c), than cells treated with 
CUR/PEDOT. These results suggest that cells were more affected by free CUR than 
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when it is encapsulated within the PEDOT NPs, again indicating that the complete 
effect of the drug would not be achieved until it is stimulated. 
Overall, results obtained in this paper indicate that CUR/PEDOT NPs can be 
considered as potential controlled release systems for therapeutic applications based on 
the anti-bacterial, anti-viral, anti-protozoal, anti-inflammatory or anti-cancer activity of 
CUR. This system allows a given dosage at desired periodical time by applying a 
harmless external voltage of only -1.25 V (i.e. from a conventional small battery). 
Moreover, after its optimization to reduce a little bit more the required voltage, one 
could envision advanced biomedical applications of the CUR/PEDOT NPs system using 
the weak electric fields naturally occurring in the body for stimulation (e.g. the intrinsic 
electric fields of cardiovascular and neuronal tissues).  
 
3. Conclusions 
Encapsulation of CUR and PIP in PEDOT NPs was achieved by in situ emulsion 
polymerization using DBSA as stabilizer and doping agent. The release behaviour of 
these two neutral drugs, which only differ in their capacity to form hydrogen bonding 
interactions with the oxidized polymer chains, was very different in absence and in 
presence of external electrostimulation. The release of CUR is controlled through the 
strength of such specific drug···ECP interactions, which become weaker when polymer 
chains are reduced applying an external negative voltage. Therefore, CUR/PEDOT NPs 
are a promising combination that efficiently controls the release of the drug through 
external stimuli. This methodology, which can be extrapolated to other neutral drugs 
with similar hydrogen bonding abilities, may be a potential strategy for treatments based 
on the programmed dosage of CUR that, among many other medicinal properties, have 
17 
 
demonstrated efficacy as anticancer agent for many types of malignancies, including 
colorectal, breast, lung, prostate, and pancreatic carcinoma.
[22d]
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Table 1. Effective diamerter (Deff) determined by SEM and DLS, drug loading ratio 
(DLR) and -potential of unloaded-PEDOT, CUR/PEDOT and PIP/PEDOT NPs. 
 
 Deff (nm) 
SEM 
Deff (nm) 
DLS 
DLR (%) -potential 
(mV) 
PEDOT  356 842 - -29.4±3.6 
CUR/PEDOT 9616 2073 5.91.6 -26.525.1 
PIP/PEDOT 292132 30417 8.00.4 -18.7±3.0 
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CAPTIONS TO FIGURES 
Figure 1. (a) Schematic representation of the chemical synthesis of PEDOT NPs by 
emulsion polymerization. (b) Trasmision electron microscopy (TEM) micrographs of 
PEDOT NPs obtained using the procedure displayed in (a). (c) Chemical structure of 
CUR and PIP. 
Figure 2. SEM images of (a) CUR/PEDOT NPs and (b) PIP/PEDOT NPs (Scale bar: 
200 nm). Effective diameter histograms derived from SEM measurements and average 
values are also displayed. 
Figure 3. AFM images (11 µm2) of (a) PEDOT, (b) CUR/PEDOT and (c) 
PIP/PEDOT NPs. The graphs displayed in panels (d-e) corresponds to the profile of the 
selected particles. 
Figure 4. FTIR spectra of (a) PEDOT NPs, CUR and CUR/PEDOT NPs; and (b) 
PEDOT NPs, PIP and PIP/PEDOT NPs.  
Figure 5. Cumulative drug release comparison between drug/PEDOT NPs and free 
drug (control) dispersed in aquous solutions and dyalised against PBS+0.5% Tween 20, 
the previous PBS solution with 10% EtOH, and with 70% EtOH: (a) CUR and (b) PIP.  
Figure 6. (a) Camera image of the three electrodes set-up for the electrochemical 
characterization of unloaded PEDOT and drug/PEDOT NPs. The red arrow points out 
released CUR in experiments with CUR/PEDOT NPs. WE, CE and RE refer to the 
working electrode, the counter electrode and the reference electrode, respectively. 
Cyclic voltammograms for (b) unloaded PEDOT NPs, (c) CUR/PEDOT NPs and (d) 
and PIP/PEDOT NPs recorded from –1.5 to 1.0 V at different varying scan rates (10, 
20, 40, 60, 80, 100, 200, 300 and 400 mV/s) using PBS 1 (pH 7.4) as electrolyte 
medium. Variation of the current density (jp) at the anodic and cathodic peaks (e) of 
CUR and at the anodic peak (f) of PIP against the square root of the scan rate. 
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Figure 7. Effect of (a,c) voltage with time constant (3 min) and (b,d) of time with 
voltage constant (-1.25 V) on drug release for drug/PEDOT NPs: (a,c) CUR and (b,d) 
PIP (n = 6). The percentage of released drug is expressed with respect to the total 
amount of loaded drug. 
Figure 8. (a) Cytotoxicity studies of PEDOT NPs and DBSA on PC3 amd MCF-7 
cells for 24 h. Although they are represented in the same graphic, assays with PEDOT 
NPs and DBSA were performed independently. (b) Cytotoxicity evaluation of CUR and 
CUR/PEDOT NPs on PC3 and MCF-7 cells for 24 h. Values are the mean of 3 samples 
and bars indicate their standard deviation. Greek letters on the columns/points refer to 
significant differences when the 2-way ANOVA and Tukey's multiple comparisons test 
are applied: α, δ, β indicate significant differences observed within the specific 
concentration group with p-values lower than 0.05, 0.001 and 0.0001, respectively. 
Figure 9. (a) High magnification fluorescent images of PC3 and MCF-7 cells 
incubated with nothing (control), PEDOT NPs, CUR and CUR/PEDOT NPs for 24 h. 
Scale bars represent 40 µm. (b) Low magnification cell images of  PC3 and MCF-7 
incubated with CUR/PEDOT NPs for 24 h. Scale bars represent 100 µm. For each 
panel, the images from left to right showed cell nuclei stained by Hoechst (blue), CUR 
fluorescence (green) and overlays of both images. (d) Cell circularity assessed by 
ImageJ software. β indicates significant differences with a p-value lower than 0.0001 
when a t-test is performed.  
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Table of contents entry:  
An electric field responsive polymeric nanoparticles system for programmed drug 
delivery is presented. More specifically, curcumine loaded into stabilized poly(3,4-
ethylenedioxythiophene) electroactive nanoparticles is released by applying a controlled 
external voltage. Curcumine···polymer interactions are crucial to regulate the release. 
This non-toxic biocompatible system is of potential use for advanced biomedical 
applications. 
 
 
